STEM CELL THERAPIES FOR ENTERIC NEUROPATHIES
Dr Lincon Stamp,
Senior Research Fellow & Group Leader,
Department of Anatomy and Physiology,
School of Biomedical Sciences,
The University of Melbourne, Victoria, Australia
RESEARCHER PROFILE
Filmed in Melbourne, Australia | October 2025
Dr Stamp is a Group Leader in the Department of Anatomy and Physiology at the University of Melbourne, Australia. Dr Stamp’s PhD research (with Prof Martin Pera, Monash University) focused on the derivation of hepatopancreatic progenitors from human embryonic stem cells. He then joined the lab of Dr Don Newgreen at the Murdoch Childrens Research Institute where he began working on development of the enteric nervous system (ENS), before joining Prof Heather Young’s lab at the University of Melbourne, where he focused on developing a stem cell therapy to treat gut motility disorders such as the paediatric enteric neuropathy Hirschprung disease.
His lab, which he runs together with Dr Marlene Hao, is now focused on the development, plasticity, and cell and gene therapies for the digestive system, with a particular focus on the enteric nervous system.
Dr Stamp has a strong national and international network of collaborators, including key clinical and consumer connections, and has published high impact studies in top tier journals including Gastroenterology, JCI and Nature Reviews Gastroenterology and Hepatology.
He has had success at securing significant government (ARC, MRFF), philanthropic (NSCFA, REACH Foundation) and industry (Takeda Pharmaceuticals) funding, has strong ties within the Australian and international stem cell communities, and is the currently the President of the Australasian Society for Stem Cell Research (ASSCR).
Source: Supplied
https://orcid.org/0000-0002-8925-7894
-
Pregnancy in women with chronic kidney disease
Professor Shilpanjali Jesudason is an academic nephrologist and Head of Department at the Royal Adelaide Hospital’s Central Northern Adelaide Renal and Transplant Service, South Australia.
From 2017-2020, she was the Clinical Director of Kidney Health Australia, the peak body for patients with kidney disease. In this role she developed a passion for advancing kidney disease education in primary care.
-
Targeting chemotherapy resistance in ovarian cancer patients
Dr Alex Cole, from the Centenary Institute’s Centre for Biomedical AI, is now leading the research focused on developing a new treatment to counteract a protein called follistatin (FST), known for making ovarian cancer cells resistant to chemotherapy.
By employing cutting-edge molecular biology and directed evolution techniques, the project aims to create nanobodies—small, precise molecules—that can block FST. If successful, these nanobodies could enhance the effectiveness of chemotherapy and improve ovarian cancer treatment rates.
-
Food and fasting periods as medicine to prevent disease
Professor Leonie Heilbronn is based at the South Australian Health and Medical Research Institute (SAHMRI), where she leads the Obesity and Metabolism laboratory. Her research is at the interface between basic and clinical science. She is internationally recognised for her work in nutritional modulation in humans and has made major contributions to our current understanding of mechanisms underlying conditions such as insulin resistance, particularly inflammation and lipid metabolism. She has also contributed significantly to current concepts of caloric restriction (CR), intermittent fasting (IF) and time restricted eating (TRE) in humans. She has published more than 110 peer reviewed papers in scientific journals and is an Associate Editor of Obesity, and Obesity Research and Clinical Practice.
